secwatch.observer — SEC 8-K summary
======================================

Issuer:     Glucotrack, Inc. (GCTK)
CIK:        0001506983
Form:       8-K
Filed at:   2025-03-31T23:59:59+00:00
Accession:  0001641172-25-001831
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Glucotrack FY2024 net loss $22.6M; completes first human CBGM study, expects IDE in Q4 2025
--------------------------------------------------------------------------------

- Net loss of $22.6M vs $7.1M in 2023; R&D expense $9.5M (+$4.8M YoY) on increased product development activities.
- Cash $5.6M at Dec 31, 2024; pro forma $11.9M after Q1 2025 offerings; raised $16.3M since Nov 2024.
- First human clinical study of CBGM met primary endpoint with no device-related serious adverse events.
- Appointed new CFO, VP Regulatory, VP Clinical Ops; expanded Medical Advisory Board.
- Anticipates IDE approval from FDA in Q4 2025; long-term study in Australia expected Q2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1506983/000164117225001831/0001641172-25-001831-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1506983/000164117225001831/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-001831

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer